Moderator: Larus S. Gudmundsson (he/him/his) – University of Iceland
### he/him/his @@@ Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety ### 1061393###Moderator###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety###Moderator: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
### @@@ Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland. ### 1900347###Speaker###Professor, University of Iceland; Chief Physician, Landspitali University Hospital.###Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.###Speaker: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
### he/him/his @@@ Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland ### 1901666###Speaker###Chief Epidemiologist###Directorate of Health Iceland###Speaker: Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland
### she/her/hers @@@ Menno van der Elst (he/him/his) – Dutch Medicines Evaluation Board ### 1901668###Speaker###Member###Dutch Medicines Evaluation Board###Speaker: Menno van der Elst (he/him/his) – Dutch Medicines Evaluation Board
### he/him/hisModerator: Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
### she/her/hers @@@ Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research ### 1046831###Moderator###Professor and Director###Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research###Moderator: Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research
### he/him/his @@@ Anne M. Butler, PhD, MS – Washington University School of Medicine ### 1062638###Speaker###Assistant Professor###Washington University School of Medicine###Speaker: Anne M. Butler, PhD, MS – Washington University School of Medicine
### @@@ Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University ### 1062566###Speaker###Assistant Professor###McGill University###Speaker: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
### he/him/his @@@ Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen ### 1302750###Speaker###Professor###Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen###Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen
###Moderator: Maurizio Sessa, PharmD – University of Copenhagen
### @@@ Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania ### 1359970###Moderator###Associate Professor of Medicine and Epidemiology###Perelman School of Medicine at the University of Pennsylvania###Moderator: Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania
### he/him/his @@@ Andrew Bate – GlaxoSmithKline ### 1088314###Speaker###VP & Head, Safety Innovation & Analytics, Global Safety###GlaxoSmithKline###Speaker: Andrew Bate – GlaxoSmithKline
### @@@ Larus S. Gudmundsson (he/him/his) – University of Iceland ### 1901667###Speaker###Associate Professor###University of Iceland###Speaker: Larus S. Gudmundsson (he/him/his) – University of Iceland
### he/him/his @@@ David O. Arnar – University of Iceland ### 1901688###Speaker###Professoe###University of Iceland###Speaker: David O. Arnar – University of Iceland
###Moderator: Andrew Bate – GlaxoSmithKline
### @@@ Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP – Research Triangle Institute ### 1061396###Moderator###VP Epidemiology###Research Triangle Institute###Moderator: Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP – Research Triangle Institute
### @@@ Alison Cave, PhD – Medicines and Healthcare products Regulatory Agency (UK) ### 1901771###Speaker###Chief Safety Officer###Medicines and Healthcare products Regulatory Agency (UK)###Speaker: Alison Cave, PhD – Medicines and Healthcare products Regulatory Agency (UK)
### @@@ Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada ### 1358167###Speaker###Professor###Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada###Speaker: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
### he/him/his @@@ Jamie Geier (she/her/hers) – Novartis Pharma AG ### 1359033###Speaker###Global Head, Quantitative Safety & Epidemiology###Novartis Pharma AG###Speaker: Jamie Geier (she/her/hers) – Novartis Pharma AG
### she/her/hersPresenting Author: Meghan Cupp Buxton, BSc, MPH (she/her/hers) – Department of Epidemiology, Brown University School of Public Health
### she/her/hers @@@ Francesca L. Beaudoin, MD, PhD – Department of Epidemiology, Brown University School of Public Health ### 1358486###Author###Associate Professor###Department of Epidemiology, Brown University School of Public Health###Author: Francesca L. Beaudoin, MD, PhD – Department of Epidemiology, Brown University School of Public Health
### @@@ Kaleen N. Hayes, PharmD, PhD (she/her/hers) – Brown University School of Public Health, Providence, Rhode Island, USA ### 1062830###Author###Assistant Professor###Brown University School of Public Health, Providence, Rhode Island, USA###Author: Kaleen N. Hayes, PharmD, PhD (she/her/hers) – Brown University School of Public Health, Providence, Rhode Island, USA
### she/her/hers @@@ Melissa R. Riester, PharmD – Brown University School of Public Health ### 1302727###Author###Research Scientist###Brown University School of Public Health###Author: Melissa R. Riester, PharmD – Brown University School of Public Health
### @@@ Sarah Berry, MD, MPH – Department of Medicine, Beth Israel Deaconess Medical Center ### 1659409###Author###Associate Professor of Medicine###Department of Medicine, Beth Israel Deaconess Medical Center###Author: Sarah Berry, MD, MPH – Department of Medicine, Beth Israel Deaconess Medical Center
### @@@ Richa Joshi, MS, MBA – Department of Health Services, Policy, and Practice, Brown University School of Public Health ### 1655733###Author###Data Science Analyst###Department of Health Services, Policy, and Practice, Brown University School of Public Health###Author: Richa Joshi, MS, MBA – Department of Health Services, Policy, and Practice, Brown University School of Public Health
### @@@ Andrew R. Zullo, PharmD, PhD (he/him/his) – Brown University School of Public Health ### 1302736###Author###Associate Professor###Brown University School of Public Health###Author: Andrew R. Zullo, PharmD, PhD (he/him/his) – Brown University School of Public Health
### he/him/his OP3-6Presenting Author: Oliver W. Scott, BHSc (first class hons) – University of Auckland
### @@@ Sandar TinTin, PhD – University of Auckland ### 1358076###Author###Senior Research Fellow###University of Auckland###Author: Sandar TinTin, PhD – University of Auckland
### @@@ Sixten Harborg, PhD/MD student – Aarhus University ### 1900223###Author###PhD student###Aarhus University###Author: Sixten Harborg, PhD/MD student – Aarhus University
### @@@ Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board ### 1900224###Author###Oncologist###Waikato District Health Board###Author: Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board
### @@@ Ross Lawrenson, MD – University of Waikato ### 1900225###Author###Professor in Population Health###University of Waikato###Author: Ross Lawrenson, MD – University of Waikato
### @@@ Mark Elwood, MD – University of Auckland ### 1358078###Author###Professor of Cancer Epidemiology###University of Auckland###Author: Mark Elwood, MD – University of Auckland
### OP2-6Presenting Author: Steve Ferreira Guerra – McGill University
### @@@ Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada ### 1358167###Author###Professor###Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada###Author: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
### he/him/his @@@ Michal Abrahamowicz, PhD – McGill University ### 1358206###Author###Professor###McGill University###Author: Michal Abrahamowicz, PhD – McGill University
### OP4-4Presenting Author: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1062759###Author###Researcher###Centre for Pharmacoepidemiology, Karolinska Institutet###Author: Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Vidar Hjellvik, PhD – Norwegian Institute of Public Health ### 1358617###Author###Statistician###Norwegian Institute of Public Health###Author: Vidar Hjellvik, PhD – Norwegian Institute of Public Health
### @@@ Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1360037###Author###Biostatistician###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### she/her/hers @@@ Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway ### 1360035###Author###Professor, consultant neurologist###NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway###Author: Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway
### @@@ Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1062595###Author###PhD candidate###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales ### 1359563###Author###Senior Biostatistician###School of Population Health, University of New South Wales###Author: Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales
### he/him/his @@@ Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki ### 1360036###Author###Professor###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki###Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
### @@@ Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia ### 1358233###Author###Senior Research Fellow###National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia###Author: Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
### she/her/hers @@@ Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden ### 1360225###Author###Statistician###Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden###Author: Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
### he/him/his @@@ Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health ### 1358431###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health###Author: Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health
### @@@ Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1358190###Author###Associate professor###Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1063034###Author###Chief physician, professor###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia ### 1358403###Author###Professor###School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia###Author: Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
### @@@ Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1358377###Author###Associate professor###Centre for Pharmacoepidemiology, Karolinska Institutet###Author: Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1659382###Author###Statistician###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Author: Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### @@@ Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health ### 1063219###Author###Senior researcher###Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health###Author: Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health
### @@@ Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1900239###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Author: Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Helga Zoega – University of New South Wales - Sydney ### 1358124###Author###Associate professor/professor###University of New South Wales - Sydney###Author: Helga Zoega – University of New South Wales - Sydney
### OP1-6Presenting Author: Milica Zugic, MScPharm – Department of Pharmacy, University of Oslo, Oslo, Norway
### @@@ Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo ### 1655801###Author###Postdoctoral Fellow###PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo###Author: Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1063068###Author###Associate Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### OP1-5Speaker: Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University
### he/him/his @@@ Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety ### 1061393###Speaker###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety###Speaker: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
### @@@ Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS ### 1062583###Speaker###Senior scientist###Leibniz Institute for Prevention Research and Epidemiology - BIPS###Speaker: Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS
### she/her/hers